Want to see RKDA full AI Analyst Report?
Top Page
Arcadia Biosciences
(NASDAQ:RKDA)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.41
▼(-36.56% Downside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance—declining revenue, very large ongoing losses, and persistent negative operating/free cash flow—along with a sharply reduced equity cushion. Technicals also point to a broader downtrend (price below major moving averages and negative MACD). Valuation is difficult to support given the negative P/E and no stated dividend yield.
Positive Factors
Debt-Free Balance Sheet
Zero debt and a 0.0 debt-to-equity ratio reduce mandatory financing costs and near-term creditor pressure. This gives the company more flexibility to direct limited resources toward products, licensing, or restructuring, although it does not solve losses.
Negative Factors
Revenue Contraction
TTM revenue fell about 25% year over year and the company has a choppy multi-year top-line trend. Sustained contraction can weaken scale, reduce funding for research and commercialization, and make it harder to absorb fixed operating costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
Zero debt and a 0.0 debt-to-equity ratio reduce mandatory financing costs and near-term creditor pressure. This gives the company more flexibility to direct limited resources toward products, licensing, or restructuring, although it does not solve losses.
Read all positive factors
Arcadia Biosciences (RKDA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.24M
Dividend YieldN/A
Average Volume (3M)1.09M
Price to Earnings (P/E)―
Beta (1Y)1.75
Revenue Growth-12.24%
EPS Growth17.56%
CountryUS
Employees8
SectorConsumer Defensive
Sector Strength42
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)-8.14
Shares Outstanding2,409,211
10 Day Avg. Volume3,254,407
30 Day Avg. Volume1,090,692
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.65
Price to Sales (P/S)0.56
P/FCF Ratio-0.57
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.42
Revenue Forecast (FY)$7.70M
Arcadia Biosciences Business Overview & Revenue Model
Company Description
Arcadia Biosciences, Inc. is a U.S.-based company that provides plant-derived health and well-being products. Additionally, it is actively engaged in agricultural research and development, with a particular focus on improving wheat crops. The aim ...
How the Company Makes Money
Arcadia Biosciences has historically generated revenue primarily through (1) commercialization of agricultural products and ingredients tied to its technology (including sales via distribution and retail channels where applicable) and (2) monetiza...
Arcadia Biosciences Earnings Call Summary
Earnings Call Date:May 08, 2025
(Q1-2025)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The earnings call reflected a strong start to 2025, with significant revenue growth in the Zola brand and effective cost control measures. However, challenges such as a decline in gross margin and an increase in inventory and cash consumption were noted. The pending business combination with Roosevelt Resources is a positive development, enhancing future prospects.Positive Updates
Zola Revenue Growth
Zola coconut water revenue grew 90% year-over-year, driven by a 70% increase in new distribution gains.
Negative Updates
Gross Margin Decline
The gross margin rate decreased to 43% in Q1 from 52% in Q1 of the previous year.
Read all updates
Q1-2025 Updates
Positive
Negative
Zola Revenue Growth
Zola coconut water revenue grew 90% year-over-year, driven by a 70% increase in new distribution gains.
Read all positive updates
Company Guidance
During the Arcadia Biosciences, Inc. first-quarter 2025 conference call, significant growth and strategic shifts were highlighted. The company reported a remarkable 90% year-over-year increase in revenue for its Zola coconut water, primarily due to a 70% rise in new distribution channels. Operating expenses saw a 16% reduction, despite incurring nearly half a million dollars in transaction-related fees. The gross margin stood at 43%, maintaining a trend of exceeding 30% for nine consecutive quarters. Arcadia continued to monetize its intellectual property, securing $750,000 in cash for certain soy patents, which allowed for the elimination of a $1,000,000 contingent liability. The pending business combination with Roosevelt Resources is progressing, aiming for completion by late summer, with a fixed equity share ratio of 90-10 between Roosevelt Partners and Arcadia stockholders. The call also mentioned a strong pipeline and new product innovations expected to further boost Zola's market presence. Overall, the company is focused on streamlining operations and enhancing financial performance in 2025.Arcadia Biosciences Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.75M | 4.86M | 5.04M | 4.45M | 7.42M | 6.78M |
| Gross Profit | 1.64M | 1.76M | 2.08M | 2.28M | 1.32M | -1.93M |
| EBITDA | -11.11M | -2.30M | -7.50M | -5.73M | -14.75M | -27.71M |
| Net Income | -11.13M | -2.34M | -7.04M | -13.98M | -15.38M | -14.66M |
Balance Sheet | ||||||
| Total Assets | 5.89M | 6.55M | 13.52M | 19.70M | 28.92M | 43.92M |
| Cash, Cash Equivalents and Short-Term Investments | 4.18M | 4.56M | 4.24M | 11.64M | 20.64M | 28.68M |
| Total Debt | 0.00 | 0.00 | 155.00K | 1.01M | 2.02M | 3.29M |
| Total Liabilities | 5.26M | 2.41M | 7.29M | 7.00M | 8.02M | 12.72M |
| Stockholders Equity | 633.00K | 4.14M | 6.22M | 12.84M | 21.03M | 31.09M |
Cash Flow | ||||||
| Free Cash Flow | -2.54M | -4.74M | -9.64M | -15.30M | -14.05M | -26.88M |
| Operating Cash Flow | -2.54M | -4.74M | -9.63M | -15.29M | -13.98M | -25.87M |
| Investing Cash Flow | 0.00 | 750.00K | 7.34M | -4.34M | 1.42M | 16.61M |
| Financing Cash Flow | 5.34M | 6.00K | 9.00K | 5.51M | 4.52M | 21.90M |
Arcadia Biosciences Technical Analysis
Negative
0.64
Price Trends
0.64
Negative
0.86
Negative
1.67
Negative
Market Momentum
-0.06
Positive
41.40
Neutral
43.60
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RKDA, the sentiment is Negative. The current price of 0.64 is above the 20-day moving average (MA) of 0.58, below the 50-day MA of 0.64, and below the 200-day MA of 1.67, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 41.40 is Neutral, neither overbought nor oversold. The STOCH value of 43.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RKDA.
Arcadia Biosciences Risk Analysis
Arcadia Biosciences disclosed 18 risk factors in its most recent earnings report. Arcadia Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Arcadia Biosciences Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $55.30B | 54.55 | 4.08% | 0.81% | 3.70% | -26.39% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
51 Neutral | $1.39B | -0.48 | -118.57% | 7.26% | -21.31% | -2884.91% | |
45 Neutral | $12.05M | -1.07 | 79.78% | ― | -25.50% | -905.27% | |
43 Neutral | $1.24M | -0.06 | -219.35% | ― | -12.24% | 17.56% | |
43 Neutral | $65.20M | -1.16 | -27.83% | ― | -3.54% | 56.67% | |
34 Underperform | $26.33M | -0.10 | -151.30% | ― | -31.20% | -796.06% |
* Consumer Defensive Sector Average
RKDA
Arcadia Biosciences
0.51
-3.34
-86.70%
AVD
American Vanguard
2.18
-3.08
-58.56%
FMC
FMC
10.66
-27.30
-71.92%
SEED
Origin Agritech
0.99
-0.18
-15.64%
BIOX
Bioceres Crop Solutions
0.40
-2.47
-85.92%
CTVA
Corteva
82.40
8.79
11.95%
Arcadia Biosciences Corporate Events
Executive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Arcadia Biosciences Grants CEO Bonus, Sets 2026 Meeting
Neutral
Jul 2, 2026
On July 1, 2026, Arcadia Biosciences’ board and compensation committee approved a discretionary cash bonus of $169,000 for chief executive and interim chief financial officer Thomas J. Schaefer for services in 2025, updating the previously f...
Private Placements and FinancingRegulatory Filings and Compliance
Arcadia Biosciences Announces $4 Million Private Placement
Neutral
Jun 15, 2026
On June 11, 2026, Arcadia Biosciences entered into a securities purchase agreement with an institutional accredited investor for a $4 million private placement priced at-the-market under Nasdaq rules. The deal, which closed on June 12, 2026, invol...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.